spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioIVT Publishes New Research On the Mechanisms Underlying the C-DILI Assay

BioIVT

The C-DILI™ Assay is a highly effective tool for assessing cholestatic hepatotoxicity risk of promising new drug candidates

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.1

DILI is one of the primary causes of drug development failures. As a result, sponsors endeavor to identify new drug candidates with a high DILI risk early in the development process. Early cholestatic DILI screening efforts historically focused on a compound’s potential to inhibit BSEP, a protein responsible for excretion of bile acids from the liver. However, BSEP inhibition potency is not always correlated with DILI suggesting that other mechanisms may be involved. BioIVT researchers demonstrated that BSEP inhibition ‘‘triggers’’ the activation of compensatory mechanisms that suppress bile acid synthesis and increase bile acid excretion through routes other than BSEP, thereby preventing hepatotoxicity.

“Cholestatic DILI is known to have a weak association with BSEP inhibition,” said BioIVT Study Director and Lead Author Jonathan Jackson, PhD. “For the first time, our study demonstrated the ‘link’ between BSEP inhibition and FXR, a master regulator of bile acid homeostasis. FXR activation by BSEP inhibition may explain the weak concordance between BSEP inhibition potency and cholestatic DILI incidence. Many compounds inhibit BSEP; however, liver cells can compensate for the resulting increase in bile acid concentration. In fact, clinical observations show that increases in circulating bile acids are not always associated with DILI. Our discovery suggests a new paradigm is required to accurately predict a drug candidate’s cholestatic DILI potential, and new methods are needed, such as our C-DILI Assay.”

The C-DILI Assay integrates cellular compensatory mechanisms with BSEP inhibition. Because the assay accounts for the adaptive response observed in liver cells, it has been shown to have high in vitro-in vivo correlation among compounds known to have a risk of DILI. As part of their screening and drug development processes, pharmaceutical companies use the C-DILI Assay to assess hepatotoxicity potential of their lead compounds.

Reference
1. Jonathan P. Jackson, Kimberly M. Freeman, Robert L. St. ClaireIII, Chris B. Black, and Kenneth R. Brouwer. Applied In Vitro Toxicology. http://doi.org/10.1089/aivt.2018.0011.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.
phone +1 516 483 1196
email customerservice@bioivt.com
web www.bioivt.com/
email PO Box 770, Hicksville, NY, 11802-0770
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Get on Board with a Neat Idea

Teknomek has launched a new range of anti-microbial shadow boards developed to meet the specific needs of the pharma sector. The products are made from PVC infused with Biomaster anti-bacterial silver-ion technology, which inhibits the growth of bacteria by up to 99.9%.
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

Industry Events

4th Annual Genome Editing Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 4thAnnual Genome Editing Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement